We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Fibrillation or Tachycardia (AFLOAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05213104
Recruitment Status : Recruiting
First Posted : January 28, 2022
Last Update Posted : September 7, 2022
Sponsor:
Collaborator:
Fonds de Dotation ACTION
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

Brief Summary:

About 30% of ischemic strokes are cryptogenic. Patent Foramen Ovale (PFO) is present in about 25% of the general population. In cryptogenic strokes, PFO has been shown to be overrepresented and recent intervention studies have confirmed that PFO has a causal link with stroke. In patients with recent cryptogenic stroke, these randomized studies have shown at least 50%-reduction of recurrent neurological events after PFO percutaneous closure compared with medical therapy alone. At the The risk of AF reported in these studies in certainly largely underestimated as only symptomatic and recorded episodes of AF have been declared. Patients often report palpitations without a dia gnosis of AF made on the ECG or a Holter. Long term ECG monitoring provides more accurate data on AF incidence.

Administration of flecainide has been shown to be effective in preventing AF and may be useful in preventing these AF episodes after PFO closure.

To the knowledge of the investigators, there is no study assessing the efficacy of any antiarrhythmic drug in the prevention of AF after PFO closure. AFLOAT will be the first randomized study to possibly validate flecainide to prevent AF in these patients.


Condition or disease Intervention/treatment Phase
Patent Foramen Ovale Atrial Fibrillation Cryptogenic Stroke Drug: Flecainide Phase 3

Detailed Description:

AFLOAT is a national, multicenter, randomized, controlled, open-label superiority study with a blind evaluation of all the endpoints (PROBE design).

The interventional phase is followed by an observational phase as long as the patient is implanted with the ICM during when only the data of the device will be collected.

Screening and selection occurs before the procedure of PFO closure and an inform consent form is signed.

During the procedure of PFO closure, a small ICM (CONFIRM RX, ABBOTT) providing a long-term monitoring is implanted to detect all AF or atrial flutter episodes.

Immediately after PFO closure, patients are randomly assigned, in a 1:1:1 ratio, in 3 groups : flecainide (150 mg per day in a single sustained-release dose) for 6 months (in addition to standard of care), flecainide (150 mg per day in a single sustained-release dose) for 3 months (in addition to standard Clinical follow-up is conducted during hospitalization, at 3 months (M3) and 6 months (M6-end-of-interventionnal phase) after discharge. A contrast echocardiography is recommended between 1 and 6 months. Telemonitoring provides notifications in case of arrhythmic event.

An observational period in patients who will keep the ICM beyond the 6-month follow-up period. Atrial fibrillation detection will be continued.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 186 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: randomized, controlled, open-label study with a blind evaluation of all the endpoints (PROBE design)
Masking: Single (Outcomes Assessor)
Masking Description: only outcomes assessor will be blinded to the study arm (PROBE design)
Primary Purpose: Treatment
Official Title: Assessment of Flecainide to Lower the Patent Foramen Ovale Closure Risk of Atrial Fibrillation or Tachycardia
Actual Study Start Date : March 23, 2022
Estimated Primary Completion Date : January 19, 2024
Estimated Study Completion Date : July 19, 2026

Resource links provided by the National Library of Medicine

Drug Information available for: Flecainide

Arm Intervention/treatment
Experimental: group 1 - Flecainide 150 mg 6 months
Flecainide 150 mg 6 months in addition to standard of care
Drug: Flecainide
Flecainide 150 mg 6 months in addition to standard of care
Other Name: Flecainide Acetate 150 MG

Experimental: group 2 - Flecainide 150 mg 3 months
Flecainide 150 mg 3 months in addition to standard of care
Drug: Flecainide
Flecainide 150 mg 3 months in addition to standard of care
Other Name: Flecainide Acetate 150 MG

No Intervention: group 3 - no Flecainide
to receive no additional treatment (standard of care only).



Primary Outcome Measures :
  1. percentage of patients with at least one episode of atrial arrythmia [ Time Frame: within 3 months after PFO closure ]
    percentage of patients with at least one episode of symptomatic or asymptomatic atrial arrhythmia episodes (≥30s) recorded on long-term monitoring with an insertable cardiac monitor (ICM) during the 3 months after PFO closure Atrial arrhythmia is defined as any episode of AF, atrial flutter or atrial tachycardia that lasts 30 seconds or more, in accordance with the 2012 consensus statement from the Heart Rhythm Society and others


Secondary Outcome Measures :
  1. percentage of patients with at least one episode of atrial arrythmia [ Time Frame: between the 3-months and 6-months follow-up visits ]
    Percentage of patients with at least one episode of symptomatic or asymptomatic AF episodes (≥30s) recorded on long-term monitoring with ICM during the 3-6 months period after PFO closure


Other Outcome Measures:
  1. percentage of patients with AF≥6 min [ Time Frame: within 3 months after PFO closure ]
    Percentage of patients with at least one episode of symptomatic or asymptomatic AF episodes (≥6 min) recorded on long-term monitoring with ICM device during the 3 months after PFO

  2. percentage of stroke or TIA [ Time Frame: within 6 months after PFO closure ]
    Percentage of patients with at least one episode of fatal or non-fatal stroke or Transient Ischemic Attack (TIA) during the 3 and 6 months after PFO closure

  3. Percentage of non-scheduled practitioner-consultation or hospitalization for any cardiovascular reason [ Time Frame: within 6 months after PFO closure ]
    Percentage of patients with at least one episode of non-scheduled practitioner-consultation or hospitalization for any cardiovascular reason during the 3 and 6 months after PFO closure

  4. All-cause mortality [ Time Frame: within 6 months after PFO closure ]
    All-cause mortality during the 3 and 6 months after PFO closure

  5. Rate of Flecainide-related adverse events [ Time Frame: from the Day 0 (V0) to the 6 months follow-up visit (V2) ]
    Rate of Flecainide-related adverse events

  6. Percentage of patients with at least one episode of symptomatic or asymptomatic AF [ Time Frame: from Day 0 (V0) till the ICM explantation (up to 2.5 years) ]
    Percentage of patients with at least one episode of symptomatic or asymptomatic AF episodes (≥6 min) recorded on long-term monitoring with ICM device during the whole follow-up period until battery run out or ICM removal.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • ≥ 18 years of age
  • They are candidates for a procedure of PFO closure, whatever the indication (secondary prevention of stroke, platypnoea, decompression illness…). The indication must have been confirmed by a multidisciplinary team as recommended by the Haute Autorité de Santé.
  • They are affiliated to Social Security
  • They have provided a signed written consent form ICM implantation and randomization will occur only in patients with successful PFO closure without any major complications

Exclusion Criteria:

  • History of atrial fibrillation (paroxysmal, persistent or permanent)
  • Electrocardiographic of ventricular pre-excitation or bundle-branch block (QRS >120ms)
  • Ischemic heart disease
  • Dilated or hypertrophic cardiomyopathy
  • A history of heart failure, severe valvular heart disease, left ventricular dysfunction (ejection fraction <50 percent)
  • A long QT interval or Brugada syndrome
  • The bradycardia-tachycardia syndrome (resting heart rate, ≤50 beats per minute, or repetitive sinoatrial blocks during waking hours)
  • Documentation of previous episodes of second or third-degree atrioventricular block
  • High heart rate at baseline > 100 bmp
  • Renal insufficiency (Glomerular filtration rate estimated by the Cockroft and Gault formula <30ml/min/m2),
  • Previous hypokalemia (potassium level <3 mmol per liter)
  • Suspected or known pregnancy (woman of childbearing potential must undergo a pregnancy test)
  • A known hypersensibility to flecainide or its excipients
  • Contemporaneous enrollment in an interventional clinical trial
  • Intended use of a prohibited medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05213104


Contacts
Layout table for location contacts
Contact: Giles MONTALESCOT, MD,PhD +33 1 42 16 29 18 gilles.montalescot@aphp.fr
Contact: Delphine BRUGIER, PhD +33 1 42 16 29 18 delphine.brugier-ext@aphp.fr

Locations
Layout table for location information
France
Hopital Pitié Salpetrière Recruiting
Paris, IDF, France, 75013
Contact: Giles Montalescot, MD, PhD    +33 1 42 16 29 18    gilles.montalescot@aphp.fr   
Contact: Delphine Brugier, PhD    +33 1 42 16 29 18    delphine.brugier-ext@aphp.fr   
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Fonds de Dotation ACTION
Investigators
Layout table for investigator information
Study Chair: Giles MONTALESCOT, MD,PhD Assistance Publique - Hôpitaux de Paris
Layout table for additonal information
Responsible Party: Assistance Publique - Hôpitaux de Paris
ClinicalTrials.gov Identifier: NCT05213104    
Other Study ID Numbers: APHP201110
2021-002608-10 ( EudraCT Number )
First Posted: January 28, 2022    Key Record Dates
Last Update Posted: September 7, 2022
Last Verified: December 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Assistance Publique - Hôpitaux de Paris:
cryptongenic stroke
Percutaneous Patent Foramen Ovale closure
randomized controlled trial
Patent Foramen Ovale
arrythmia
Atrial Fibrillation
flecainide
Additional relevant MeSH terms:
Layout table for MeSH terms
Ischemic Stroke
Atrial Fibrillation
Tachycardia
Foramen Ovale, Patent
Stroke
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Arrhythmias, Cardiac
Heart Diseases
Pathologic Processes
Cardiac Conduction System Disease
Heart Septal Defects, Atrial
Heart Septal Defects
Heart Defects, Congenital
Cardiovascular Abnormalities
Congenital Abnormalities
Flecainide
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action